G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Irene Ganan-Gomez,Huiying Yang,Feiyang Ma,Guillermo Montalban-Bravo,Natthakan Thongon,Valentina Marchica,Guillaume Richard-Carpentier,Kelly S. Chien,Ganiraju C. Manyam,Feng Wang,Ana Alfonso,Shu Chen,Caleb A. Class,Rashmi Kanagal-Shamanna,Justin P. Ingram,Yamini Ogoti,Ashley Rose,Sanam Loghavi,Pamela Lockyer,Benedetta Cambò,Muharrem Muftuoglu,Sarah Schneider,Vera Adema,Michael D. McLellan,J. J. Picazo De La Garza,Matteo Marchesini,Nicola Giuliani,Matteo Pellegrini,Jing Wang,Jason Walker,Ziyi Li,Koichi Takahashi,Joel D. Leverson,Carlos E. Bueso-Ramos,Michael Andreeff,Karen Clise-Dwyer,Guillermo Garcia-Manero,Simona Colla +37 more
TL;DR: In this article , the authors investigated the biological properties of the MDS HSCs that drive disease evolution, seeking to uncover vulnerabilities that could be therapeutically exploited, and uncovered that HSC architectures in MDS are potential predictive biomarkers to guide second-line treatments after HMA failure.
Journal ArticleDOI
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
Hagop M. Kantarjian,Courtney D. DiNardo,Graciela M. Nogueras-Gonzalez,Tapan M. Kadia,Elias Jabbour,Carlos E. Bueso-Ramos,Susan O'Brien,Marina Konopleva,Nitin Jain,Naval Daver,Elizabeth J. Shpall,Richard E. Champlin,Aron Simkins,Guillermo Garcia-Manero,Michael J. Keating,Xuelin Huang,Jorge E. Cortes,Sherry Pierce,Farhad Ravandi,Emil J. Freireich +19 more
TL;DR: The objective of the current study was to analyze the results from second salvage therapies in patients with AML since 2000 with regard to response and survival.
Journal ArticleDOI
MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.
Francis J. Giles,Steven J. Freedman,Alan Xiao,Gautam Borthakur,Guillermo Garcia-Manero,William G. Wierda,Steven M. Kornblau,Susan O'Brien,Donald A. Bergstrom,David A. Rizzieri +9 more
TL;DR: MK-0457 at well tolerated doses achieves myelosuppression in refractory AML and ALL patients and is on-going in the acute leukemia population with 36 mg/m 2 /hr as the current dose level under investigation.
Journal ArticleDOI
Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms
Dai Chihara,Dai Chihara,Hagop M. Kantarjian,Kate J. Newberry,Farhad Ravandi,Naval Daver,Prithviraj Bose,Courtney D. DiNardo,Naveen Pemmaraju,Tapan M. Kadia,Gautam Borthakur,Marina Konopleva,Guillermo Garcia-Manero,Uday R. Popat,Jorge E. Cortes,Srdan Verstovsek +15 more
TL;DR: Survition outcome for AML secondary to MPN remains very poor, and there has been no improvement in survival outcome since 1989.
Journal ArticleDOI
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission
Hagop M. Kantarjian,Deborah A. Thomas,Farhad Ravandi,Stefan Faderl,Guillermo Garcia-Manero,J. Shan,Sherry Pierce,Jorge E. Cortes,Susan O'Brien +8 more
TL;DR: The outcome of adults with acute lymphocytic leukemia who achieve a complete response (CR) on salvage therapy is thought to be poor, but not previously analyzed, and the effects of pretreatment factors on prognosis are defined.